Dynamics of Spike-Specific Neutralizing Antibodies Across Five-Year Emerging SARS-CoV-2 Variants of Concern Reveal Conserved Epitopes that Protect Against Severe COVID-19
Since early 2020, several SARS-CoV-2 variants of concern (VOCs) continue to emerge, evading waning antibody mediated immunity produced by the current Spike-alone based COVID-19 vaccines. This caused a prolonged and persistent COVID-19 pandemic that is going to enter its fifth year. Thus, the need remains for innovative next generation vaccines that would incorporate protective Spike-derived B-cell epitopes that resist immune evasion. Towards that goal, in this study we (i) Screened the sequences of Spike among many VOCs and identified conserved and non-conserved linear B-cell epitopes; (ii) Compared titers and neutralization antibodies specific to these conserved and non-conserved B-cell epitopes from serum of symptomatic and asymptomatic COVID-19 patients that were exposed to multiple VOCs across the 5-year COVID-19 pandemic, and (iii) Compared protective efficacy of conserved versus non-conserved B-cell epitopes against the most pathogenic Delta variant in a "humanized" ACE-2/HLA transgenic mouse model. We found robust conserved B-cell epitope-specific antibody titers and neutralization in sera from asymptomatic COVID-19 patients. In contrast, sera from symptomatic patients contained weaker antibody responses specific to conserved B-cell epitopes. A multi-epitope COVID-19 vaccine that incorporated the conserved B-cell epitopes, but not the non-conserved B-cell epitopes, significantly protected the ACE2/HLA transgenic mice against infection and COVID-19 like symptoms caused by the Delta variant. These findings underscore the importance of conserved B-cell epitopes in generating robust protective immunity against severe COVID-19 symptoms caused by various VOCs, providing valuable insights for the development of broad-spectrum next generation Coronavirus vaccines capable of conferring cross-variant protective immunity. IMPORTANCEA persistent COVID-19 pandemic continues to evolve because of a continued emergence of SARS-CoV-2 variants of concern (VOCs) that escape the antibodies induced by the current Spike-alone COVID-19 vaccines. Identifying and characterizing the protective and non-protective Spike-derived B-cell epitopes that resist immune-evasion is a paramount for the development of broad-spectrum next generation Coronavirus vaccines. The present study identified Spike-derived conserved B cell epitopes that (i) are targeted by consistent and strong antibody responses in asymptomatic COVID-19 patients across the 5-year pandemic regardless of VOCs; and (ii) provided strong protection in humanized" ACE2/HLA transgenic mice against infection and COVID-19 like symptoms caused by the most pathogenic Delta variant. The findings have the potential to inform the design of next generation Coronavirus vaccines capable of conferring cross-variant protective immunity. TWEETProtective SARS-CoV-2 Conserved Linear B Cell Epitopes Identified from Spike Protein.